A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test
暂无分享,去创建一个
F. Herth | G. Hartmann | T. Muley | R. Marrades | R. Molina | M. M. van den Heuvel | S. Holdenrieder | X. Zhi | F. Dayyani | C. Korse | K. Qian | Zhongjuan Liu | B. Wehnl | Xiaotong Zhang | Ying He | C. Engel | Kun Qian
[1] M. Perelman,et al. New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer , 2016, British Journal of Cancer.
[2] F. Koinis,et al. Small cell lung cancer (SCLC): no treatment advances in recent years. , 2016, Translational lung cancer research.
[3] G. Giaccone,et al. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. de Ruysscher,et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] B. Chan,et al. Chemotherapy advances in small-cell lung cancer. , 2013, Journal of thoracic disease.
[6] Michael Peyton,et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.
[7] M. Chalhoub,et al. Clinical Medicine Insights: Oncology R a P I D C O M M U N I C a T I O N Small Cell Lung Cancer Doubling Time and Its Effect on Clinical Presentation: a Concise Review , 2022 .
[8] Chu Chen,et al. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis , 2011, Clinical chemistry and laboratory medicine.
[9] T. Peretz,et al. The diagnostic and prognostic value of ProGRP in lung cancer. , 2009, Anticancer research.
[10] N. Viñolas,et al. Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology , 2009, Tumor Biology.
[11] K. Feldmann,et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[12] M. Leeflang,et al. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. , 2008, Clinical chemistry.
[13] James L Mulshine,et al. Lung cancer screening. , 2005, The oncologist.
[14] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[15] P. Lamy,et al. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. , 2003, Lung cancer.
[16] John Eng,et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. , 2003, JAMA.
[17] H. Dienemann,et al. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. , 2002, Anticancer research.
[18] K. Kiura,et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). , 2001, Lung cancer.
[19] H. Ohmatsu,et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. , 2000, Lung cancer.
[20] R. Simon,et al. A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. , 1996, Statistics in medicine.
[21] K. Yamaguchi,et al. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. , 1994, Cancer research.
[22] H. Liu,et al. Treatment of small cell lung cancer. , 1991, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.
[23] M. Cozijnsen,et al. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. , 1991, British Journal of Cancer.
[24] L. Qiu,et al. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[25] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[26] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[27] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[28] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.